37 registrations that name magnesium as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 37 registrations
Status
Phase
8US sites across 6 states
1
2 to 4
5 to 19
20 or more
All 37 registrations
RecruitingNCT07640685
UCLA Magnesium Formulation Athlete Study
No phase
University of California, Los Angeles
About 150 people
Started Oct 5, 2026
In plain words A study of magnesium in people 18 to 35, run by University of California, Los Angeles. It plans to enroll about 150 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 35; healthy volunteers accepted. Conditions: Athletic Performance; Recovery; Sleep.
Age 18-35 years.
Current NCAA Division I athlete at UCLA.
Actively participating in team training and/or competition.
Willing to wear a WHOOP 4.0 device continuously during the baseline and treatment periods of the study block.
4 more inclusion criteria and the exclusion criteria are on the listing.
This randomized, double-blind, placebo-controlled trial will compare magnesium glycinate, magnesium L-threonate, and placebo in UCLA varsity athletes. Participants will complete a baseline monitoring period followed by 4 weeks of blinded nightly supplementation. WHOOP 4.0 data will be used to evaluate sleep efficiency, total sleep time, sleep consistency, heart rate variability, resting heart rate, and recovery metrics. Baseline and final testing will assess selected reaction and physical performance outcomes. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06260072
Magnesium and Riboflavin Treatment for Post-Concussion Headache
Phase 2
University of Virginia
About 108 people
Started Feb 10, 2020
In plain words A Phase 2 study of magnesium in people 18 to 40, run by University of Virginia. It plans to enroll about 108 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40. Conditions: Concussion, Intermediate.
Seen at University of Virginia Student Health and Wellness Center or Emergency Department for Initial Visit for Concussion;
Less than 3 days have elapsed since their injury;
Able to swallow capsules
The exclusion criteria are on the listing.
What it tests, as registered
magnesium and riboflavin supplement
Registered summary
This clinical trial will try to determine if the supplements magnesium and riboflavin will reduce the pain and duration of headaches in persons diagnosed with a concussion. The participant will be randomized to either active magnesium and riboflavin capsules or placebo (inert) capsules. The capsules will be taken once a day for 14 days. The participant will also complete a short diary form for the 14 days and will have 3 follow up visits either by telephone or in person.
Where, as registered
1 US site in 1 state.
RecruitingNCT06904287
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
Phase 3
Wake Forest University Health Sciences
About 100 people
Started Dec 16, 2025
In plain words A Phase 3 study of magnesium in people 18 and older, run by Wake Forest University Health Sciences. It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Migraine.
Age ≥ 18 years or older
Able to provide informed consent
English speaking
Primary diagnosis of migraine. Patient with a previous diagnosis of migraine, who experience headaches with typical migraine features (e.g at least 2-3 of the following: recurrent, unilateral, pounding or throbbing in nature, associated…
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium; Placebo
Registered summary
The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.
Where, as registered
1 US site in 1 state.
RecruitingNCT07753122
Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
No phase
Fred Friedberg
About 80 people
Starts Aug 15, 2026 (estimated)
In plain words A study of magnesium in people 18 to 65, run by Fred Friedberg. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Chronic Fatigue Syndrome (CFS).
Patients aged 18-65 of both sexes
considered physically capable and willing to perform the study tasks
Meet validated phone-screen eligibility for ME/CFS criteria
Participant has internet and computer
The exclusion criteria are on the listing.
What it tests, as registered
Placebo condition; Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks.
Registered summary
This is a 16-week controlled treatment trial of an over-the -counter supplement, hydrogen water, for individuals with ME/CFS patients. An active treatment condition will be compared to a placebo-control condition. The study will also seek confirmation of heart rate variability (HRV) as a biomarker, that is, as a predictor of improvement vs. non-improvement to be assessed at treatment termination. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06902285
Magnesium-L-Threonate for Sleep Quality Post-Arthroplasty
Phase 4
University of Miami
About 64 people
Started Apr 21, 2025
In plain words A Phase 4 study of magnesium in people 18 and older, run by University of Miami. It plans to enroll about 64 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sleep; Knee Osteoarthritis.
Patients undergoing primary total knee or hip arthroplasty at the University of Miami Hospital
Patients > 18 years of age
Subjects must be capable of providing informed consent
English or Spanish-speaking
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium Threonate; Control
Registered summary
The study team is conducting a study to see if Magnesium-L-Threonate (MgT) can help improve how well participants sleep and reduce pain after total joint replacement surgery
Where, as registered
1 US site in 1 state.
RecruitingNCT07651514
The Effect of a Daily Magnesium and Melatonin Supplement on Sleep Quality in People With Nighttime Leg Cramps
No phase
StudySetGo
About 50 people
Starts Oct 10, 2026 (estimated)
In plain words A study of magnesium in people 40 to 75, run by StudySetGo. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 75; healthy volunteers accepted. Conditions: Poor Sleep Quality; Leg Cramps, Nocturnal.
Adults aged 40-75 years
Self-reported poor sleep quality (PSQI >5) at screening
Self-reported nocturnal leg cramp averaging ≥4 episodes per fortnight at screening
Capacity to understand and provide electronic informed consent
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Magnesium and melatonin based multi-ingredient dietary supplementation; Placebo
Registered summary
Participants are being invited to take part in a research study. Before deciding whether to take part, it is important for participants to understand why the research is being done and what it will involve. Purpose: This study will investigate whether a multi-ingredient nutritional supplement containing magnesium and melatonin can improve sleep quality in adults who experience disrupted sleep due to nighttime leg cramps. What participation involves: Participation lasts 8 weeks. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05837104
Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder
Phase 2
Mclean Hospital
About 40 people
Started Dec 13, 2023
In plain words A Phase 2 study of magnesium in people 18 to 50, run by Mclean Hospital. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 50. Conditions: Bipolar I Disorder; Depression, Anxiety; Stress.
Persons between the ages of 18 and 50
DSM V diagnosis of bipolar I disorder, onset of illness in the last 10 years
Minimum of two of the following symptoms on the Hamilton Rating Scale of Depression HAM-D (HAM-D, 17 item): depressed mood, feelings of guilt, anxiety-psychic, anxiety-somatic, somatic symptoms-general, somatic symptoms-gastrointestinal.
Young Mania Rating Scale (YMRS) scores of less than 15
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Magnesium vitamin B6; Placebo
Registered summary
This is a randomized, double-blind, placebo-controlled proof-of-concept clinical trial to assess the efficacy and safety of Magnesium-vitamin B6in combination with treatment as usual for treating symptoms of depression, stress, and anxiety in patients with first episode bipolar I disorder.
Where, as registered
1 US site in 1 state.
RecruitingNCT07173855
Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
Phase 4
Scarborough General Hospital
About 3,853 people
Started Nov 25, 2025
In plain words A Phase 4 study of magnesium in people 16 and older, run by Scarborough General Hospital. It plans to enroll about 3,853 people at 6 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 16 and older. Conditions: Critical Illness.
Age 16 years or older
Admission orders written to a medical-surgical intensive care unit at a participating site
In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The full summary is on the listing.
Where, as registered
No US site; Canada (6).
RecruitingNCT07655817
Oral Versus Intravenous Magnesium on Emergence Delirium
Phase 2 and 3
Tanta University
About 360 people
Started Jul 1, 2026
In plain words A Phase 2 and 3 study of magnesium in people 4 to 7, run by Tanta University. It plans to enroll about 360 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 4 to 7. Conditions: Magnesium; Emergence Delirium; Children; Adenotonsillectomy.
Children aged 4 to 7 years
American Society of Anesthesiologist (ASA) Status I or II
Planned for an adenotonsillectomy procedure under sevoflurane general anesthesia.
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium glycinate; Magnesium sulfate injection; Oral juice and intravenous saline
Registered summary
This prospective randomized controlled study will be conducted to compare the effects of preoperative oral magnesium and intraoperative IV magnesium on the incidence and severity of emergence delirium in children undergoing adenotonsillectomy using sevoflurane anesthesia.
Where, as registered
No US site; Egypt (1).
RecruitingNCT05018221
Better Evidence and Translation for Calciphylaxis
Phase 3
University of Sydney
About 350 people
Started Aug 26, 2021
In plain words A Phase 3 study of magnesium in people 18 and older, run by University of Sydney. It plans to enroll about 350 people at 21 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Calciphylaxis.
Currently receiving haemodialysis, or peritoneal dialysis that can be converted to haemodialysis, with planned ongoing haemodialysis a minimum of three times per week for at least the duration of the protocolised calciphylaxis treatments…
Have a new calciphylaxis ulcer present for less than 10 weeks
Age ≥ 18 years
Eligible for randomisation in at least one recruiting domain
1 more inclusion criterion and the exclusion criteria are on the listing.
This global platform study will evaluate multiple interventions, across several domains of therapeutic care, in adult patients with kidney failure and newly diagnosed calciphylaxis.
Where, as registered
No US site; Australia (16), New Zealand (5).
RecruitingNCT03088852
Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards
Phase 4
Frieda Wolf
About 330 people
Started May 10, 2017
In plain words A Phase 4 study of magnesium in people 18 to 90, run by Frieda Wolf. It plans to enroll about 330 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90. Conditions: Hypomagnesemia.
Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent.
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium Citrate 100 MG
Registered summary
Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The full summary is on the listing.
Where, as registered
No US site; Israel (1).
RecruitingNCT05216328
Prevention of Opioid-induced Constipation in Patients With Advanced Cancer
Phase 4
Amsterdam UMC, location VUmc
About 258 people
Started Dec 2, 2022
In plain words A Phase 4 study of magnesium in people 18 and older, run by Amsterdam UMC, location VUmc. It plans to enroll about 258 people at 13 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Constipation, Opioid-Induced.
Patients with advanced cancer (≥18 years);
Starting with slow release or transdermal opioids for pain;
Able to complete a Dutch questionnaire. Previous treatment with opioids is allowed, if discontinued more than 4 weeks ago.
The exclusion criteria are on the listing.
What it tests, as registered
Macrogol Only Product in Oral Dose Form; Magnesium hydroxide 724mg
Registered summary
More than 70% of patients with cancer in the palliative phase have pain that often requires treatment with opioids (morphine-like agents). Constipation occurs in 59% of patients treated with opioids. Opioid-induced constipation (OIC) has consequences that range from daily discomfort with social insecurity and disability to intestinal obstruction. It leads to limitations in self-management, a reduced quality of life and a risk of the need for more care. The full summary is on the listing.
Where, as registered
No US site; Netherlands (13).
RecruitingNCT06922669
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
No phase
General Hospital of Shenyang Military Region
About 232 people
Started Jun 24, 2025
In plain words A study of magnesium in people 18 to 80, run by General Hospital of Shenyang Military Region. It plans to enroll about 232 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Drug Induced Liver Injury.
Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially patients with hyperbilirubinemia. However, the available evidence remains controversial and its quality is also very limited. Herein, a multicenter randomized controlled trial (RCT) has been designed to explore the efficacy and safety of glucocorticoids in patients with acute DILI and hyperbilirubinemia.
Where, as registered
No US site; China (1).
RecruitingNCT07149649
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2 and 3
Swiss Cancer Institute
About 230 people
Starts Aug 2026 (estimated)
In plain words A Phase 2 and 3 study of magnesium in people 18 and older, run by Swiss Cancer Institute. It plans to enroll about 230 people at 11 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer.
Written informed consent according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures;
Histologically or cytologically confirmed diagnosis of NSCLC (adeno-, squamous-, large cell carcinoma or NSCLC not otherwise specified);
Patients planned for systemic first-line therapy with a combination of a carboplatin-based doublet chemotherapy and a PD-1 / PD-L1 targeting immune checkpoint inhibitor;
Patients not eligible for immune checkpoint inhibitor monotherapy irrespective of PD-L1 expression;
19 more inclusion criteria and the exclusion criteria are on the listing.
This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes. Magnesium is important for immune function, and low levels during chemotherapy are common. Participants are randomly assigned to receive either magnesium or a placebo, both as infusions and tablets. Neither the participants nor the doctors know who receives which treatment. The study compares the two groups to see if magnesium helps and how well it is tolerated.
Where, as registered
No US site; Switzerland (11).
RecruitingNCT05862454
Magnesium Injection Ensures Steroid Avoidance During Vaccine, Viremia or Immunocompromise
Observational
Salem Anaesthesia Pain Clinic
About 150 people
Started Jul 2, 2020
In plain words An observational study of magnesium in people 20 to 99, run by Salem Anaesthesia Pain Clinic. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 to 99; healthy volunteers accepted. Conditions: Steroid Metabolism Disorder.
adult chronic pain patients
previous interventional injection therapy
consent for interventional injection therapy
good treatment compliance
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Magnesium
Registered summary
Steroid injections are used for interventional pain management. However, their side-effect of immunosuppression may increase the risk of infections. Magnesium is an alternative anti-nociceptive injection that may be used instead of steroids. Prospective observational study of patients who received magnesium injection for interventional pain therapy, instead of steroid injection. Post-injection data collection includes numerical rating pain score, and sleep quality score. Pain is measured using the numeric pain rating scale. Sleep score is measured using the Likert sleep scale. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT07305519
The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in Preventing Preterm Birth:
No phase
University of Roma La Sapienza
About 150 people
Started Apr 1, 2026
In plain words A study of magnesium in female participants 18 and older, run by University of Roma La Sapienza. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Preterm Labor.
Signed informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium-PEA-HMW Hyaluronic Acid-Vitamin B6-Vitamin D + Vaginal Progesterone; Standard Treatment (Guideline-Based)
Registered summary
The aim of the study is to assess the effect of a combination of Magnesium, Palmitoylethanolamide, high-molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in women at risk of preterm birth (PTB).
Where, as registered
No US site; Italy (1).
RecruitingNCT07585045
Effectiveness of Oral Magnesium Supplementation in Fibromyalgia Patients Not Responding to Standard Treatment
No phase
Shaikh Zayed Hospital, Lahore
About 86 people
Started Apr 16, 2026
In plain words A study of magnesium in people 18 to 65, run by Shaikh Zayed Hospital, Lahore. It plans to enroll about 86 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Fibromyalgia.
Patients diagnosed with FM according to the American College of Rheumatology (ACR) 2016 criteria
Age: 18-65 years.
Not responding to conventional treatment (e.g., amitriptyline, duloxetine, pregabalin) for at least 8 weeks
Patients giving informed consent for enrollment in the study.
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium glycinate; Vitamins
Registered summary
Fibromyalgia is a complex widespread pain disorder. OBJECTIVES To evaluate the effectiveness of oral magnesium supplementation in reducing symptom severity among fibromyalgia patients who have not responded to standard treatment, using validated scoring systems such as the Fibromyalgia Impact Questionnaire Revised (FIQR).
Where, as registered
No US site; Pakistan (1).
RecruitingNCT07298564
Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)
No phase
Behnood Abbasi
About 84 people
Starts Jan 30, 2026 (estimated)
In plain words A study of magnesium in female participants 19 to 65, run by Behnood Abbasi. It plans to enroll about 84 people at 1 site, none in the US.
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age and is associated with metabolic abnormalities such as insulin resistance, dyslipidemia, and hormonal imbalance, which may lead to infertility and hirsutism. Despite the availability of several pharmacological treatments, many therapies fail to effectively address the underlying metabolic and endocrine dysfunctions of PCOS. The full summary is on the listing.
Where, as registered
No US site; Iran (1).
RecruitingNCT07633080
Magnesium Bisglycinate in Major Depressive Disorder
No phase
All India Institute of Medical Sciences, Bhubaneswar
About 84 people
Started Jun 12, 2026
In plain words A study of magnesium in people 18 to 65, run by All India Institute of Medical Sciences, Bhubaneswar. It plans to enroll about 84 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Major Depressive Disorder.
Patients with a diagnosis of Major Depressive Disorder (MDD) as per DSM-5 criteria.
Patients of either sex within the age group of 18-65 years.
Mild to severe depression, defined as a baseline MADRS score ≥7.
Currently receiving a stable dose of antidepressant monotherapy (SSRI or SNRI) in equivalent doses.
1 more inclusion criterion and the exclusion criteria are on the listing.
Depression is a common illness that can affect a person's mood, sleep, energy, ability to work, and overall quality of life. While medicines are available to treat depression, many people do not get complete relief from their symptoms. This study will evaluate whether adding a magnesium supplement in the form of magnesium bisglycinate to regular antidepressant treatment can help improve symptoms of depression. The full summary is on the listing.
Where, as registered
No US site; India (1).
RecruitingNCT07483502
The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator "WellBiome" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings.
No phase
Hull University Teaching Hospitals NHS Trust
About 80 people
Started Apr 9, 2026
In plain words A study of magnesium in people 50 to 80, run by Hull University Teaching Hospitals NHS Trust. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 80. Conditions: Cardiovascular Diseases (CVD); Cardiovascular Surgery.
Aged 50-80
BMI ≥ 25-40kg/m²
Waist circumference >94cm (men) and 88cm (women)
HbA1c 42-58 mmol/mol (6.0-7.5 old HbA1c units)
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
5g of prebiotic fibre and 300mg of magnesium (WellBiome); 5g of maltodextrin
Registered summary
More than 7.4 million people in the UK are currently waiting for surgery. Behind that number are real people-patients preparing mentally and physically for procedures ranging from joint replacements to major heart and abdominal operations. This research forms part of a broader strategy known as prehabilitation - preparing the body before surgery to improve outcomes afterward. For patients waiting for surgery, it represents a shift from passive waiting to active preparation. Heart surgery for bypass or valve replacements results in inevitable yet controlled trauma. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (1).
RecruitingNCT06959251
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia
No phase
Instituto Nacional de Enfermedades Respiratorias
About 60 people
Started Oct 2, 2025
In plain words A study of magnesium in people 5 and older, run by Instituto Nacional de Enfermedades Respiratorias. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 5 and older. Conditions: Primary Ciliary Dyskinesia.
Any sex.
Age of 5 years or more.
Diagnosis of primary ciliary dyskinesia (PCD) established according to international recommendations (Shapiro et al. Am J Respir Crit Care Med 2018;197(12):e24-e39, and Shapiro et al. Ped Pulmonol 2016;51:115-132).
Without respiratory exacerbations of PCD in the previous 30 days.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Glycine; Magnesium+thiamine; Placebo
Registered summary
* Patients with primary ciliary dyskinesia (PCD) have trouble with clearing their bronchi from mucus, which in the long-term may produce severe damage to the lungs. Currently, there is no specific treatment for PCD beyond supportive measures such as airway hydration and postural drainage. * Glycine is an amino acid with anti-inflammatory properties that proved to be beneficial in another disease with problematic airway clearance, cystic fibrosis. * Magnesium participates in many crucial chemical reactions, including some that might favor fluidification and mobilization of mucus. The full summary is on the listing.
Where, as registered
No US site; Mexico (1).
RecruitingNCT06996171
Comparative Efficacy of Magnesium Supplement and Melatonin Congener in Young Adults With Primary Insomnia
No phase
CMH Kharian Medical College
About 60 people
Started May 5, 2025
In plain words A study of magnesium in people 18 to 40, run by CMH Kharian Medical College. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40. Conditions: Primary Insomnia.
Age 18-40 years
Gender: Male and Females (Non-pregnant \& Non lactating)
Diagnosed cases of primary insomnia according to following criteria:
Difficulty falling asleep, staying asleep or nonrestorative sleep
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Magnesium glycinate; Melatonin
Registered summary
Sleep is essential for our overall health and well-being, much like food and water. It plays a vital role in numerous bodily functions. Many studies have been conducted to determine the efficacy of melatonin congeners and Mg supplements in patients with insomnia separately. This study aims to compare the efficacy of melatonin and magnesium supplements in young adults with primary insomnia. Most insomnia studies focus on older adults or individuals with comorbidities. Targeting otherwise healthy young adults brings age-specific relevance and novel insight.
Where, as registered
No US site; Pakistan (1).
Not yet recruitingNCT07708857
Magnesium Supplement for Sleep Quality in Women With Poor Sleep
No phase
Jacksonville University
About 50 people
Starts Sep 2026 (estimated)
In plain words A study of magnesium in female participants 35 to 60, run by Jacksonville University. It plans to enroll about 50 people at 1 US site.
Women aged 35-60 U.S.-based, fluent in English Insomnia Severity Index score ≥8 (poor/subclinical insomnia) and <22 (excluding severe clinical insomnia) No formal sleep disorder diagnosis Consistent bedtime routine (+/-1 hr) Not currently…
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium Breakthrough; Placebo
Registered summary
This study will test whether a magnesium supplement (Magnesium Breakthrough) improves sleep quality and mood in women ages 35 to 60 who have poor sleep but no diagnosed sleep disorder. Participants will take the magnesium supplement for two weeks and a matched placebo for two weeks, in random order, separated by a one-week washout period. Neither participants nor study staff will know which product is being taken during each period. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07567963
Magnesium Supplementation as a Nutritional Intervention in Sarcopenia
No phase
Escola Superior de Saúde - Universidade do Algarve
About 352 people
Starts Jun 1, 2026 (estimated)
In plain words A study of magnesium in people 70 and older, run by Escola Superior de Saúde - Universidade do Algarve. It plans to enroll about 352 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 70 and older; healthy volunteers accepted. Conditions: Sarcopenia.
Adults aged 70 years or older
Community-dwelling individuals residing in the eastern Algarve region of Portugal
Not hospitalized at the time of recruitment
Ability to participate in study assessments, regardless of mobility status
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Citrate Magnesium Supplementation; Placebo
Registered summary
Sarcopenia is a progressive condition common in older adults and is characterized by loss of muscle strength, muscle mass, and physical performance. It is associated with an increased risk of falls, disability, reduced independence, and poorer quality of life. Nutritional interventions are recommended as part of sarcopenia management; however, evidence regarding the role of specific micronutrients remains limited. Magnesium is an essential mineral involved in muscle contraction, neuromuscular function, energy production, and inflammation regulation. The full summary is on the listing.
Where, as registered
No US site; Portugal (1).
Not yet recruitingNCT03567824
MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus
Phase 2
Pharmalyte Solutions LLC
About 200 people
Starts Mar 1, 2026 (estimated)
In plain words A Phase 2 study of magnesium in people 18 and older, run by Pharmalyte Solutions LLC. It plans to enroll about 200 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Hypomagnesemia in Type 2 Diabetic Patients.
Females and males with Type 2 diabetes mellitus
Body Mass Index between 18 to 40 kg/m2, inclusive, at Screening
Hypomagnesemia defined as serum magnesium ≤ 1.5 mg/dL at Screening
Females must be non-pregnant, non-lactating, and have a negative serum pregnancy test before enrollment.
To determine the effect of MLD10 (magnesium L-lactate dihydrate extended-release caplets) 10 mEq BID on serum magnesium in Type 2 diabetic patients with hypomagnesemia.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07685613
A Virtual Clinical Trial to Examine the Effect of Magnesium Choline Citrate on Cognitive Function and Anxiety in Healthy Adolescents and Adults
No phase
Nutrisol, LLC
About 200 people
Starts Nov 2026 (estimated)
In plain words A study of magnesium in people 9 and older, run by Nutrisol, LLC. It plans to enroll about 200 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 9 and older; healthy volunteers accepted. Conditions: Cognitive Function; Anxiety.
Males and females 9 years and older
Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g.
Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
Double-barrier method
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Magnesium Choline Citrate; Placebo
Registered summary
The goal of this clinical trial is to examine the effect of Magnesium Choline Citrate on cognitive function and anxiety in healthy adolescents and adults. The main questions it aims to answer are: * What is the change in cognitive function, as assessed by the PROMIS Cognitive Function- Short Form 8a (≥18 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo? * What is the change in cognitive function, as assessed by the Pediatric Cognitive Function - Short Form 7a (9 - 17 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo? Researchers… The full summary is on the listing.
Where, as registered
No US site; Canada (1).
Not yet recruitingNCT06966102
Lidocaine Infusion Versus Magnesium Infusion in Decreasing Fentanyl Requirements in Endoscopic Sinus Surgeries
Phase 4
Cairo University
About 156 people
Starts May 10, 2025 (estimated)
In plain words A Phase 4 study of magnesium in people 21 to 60, run by Cairo University. It plans to enroll about 156 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 60. Conditions: Enhanced Recovery; Functional Endoscopic Sinus Surgery; Lidocaine; Magnesium Sulphate; Perioperative Pain.
Age from 21 to 60 years.
Both genders.
American society of Anesthesiologist (ASA) physical status I-II
Scheduled for functional endoscopic sinus surgery under general anesthesia.
The exclusion criteria are on the listing.
What it tests, as registered
Lidocaine group; Magnesium group; Control group
Registered summary
Enhanced recovery after ear, nose and throat surgery is based on multimodal and multidisciplinary perioperative interventions to decrease postoperative pain. Functional endoscopic sinus surgery is a surgical management for chronic rhinosinusitis. Although a common procedure, there is a lack of knowledge about perioperative pain and specific pain management after such a procedure. Most of recommendations given in guidelines for postoperative pain management in nasal surgery and sinus surgery are subsumed under head and neck surgery. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT07528612
MAG-PAIN - MAGnesium for Postoperative Analgesia In the Newly Delivered
Phase 2
Region Halland
About 150 people
Starts Apr 2, 2026 (estimated)
In plain words A Phase 2 study of magnesium in female participants 18 and older, run by Region Halland. It plans to enroll about 150 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Postoperative Pain; Quality of Recovery (QoR-15); Pain Prediction; Magnesium Sulfate; Pain Interference; Self-Efficacy.
Adult
Planned or non-urgent c-section in regional anesthesia
Ability to read, speak and understand infromation in Swedish
Oral and written consent
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium group; Placebo
Registered summary
The study aims to investigate whether a commonly used medicine, magnesium, can help reduce pain after a Caesarean section. A total of 150 participants will be included. Their usual medical care will not change, and participation is entirely voluntary. The purpose of the study is to determine whether magnesium can improve pain relief after surgery and support faster recovery and bonding with the newborn. Before the operation, potential participants will receive a text message containing a short questionnaire about their background and their expectations regarding postoperative pain. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07779577
Serum Magnesium Levels in Patients Diagnosed With Lipedema
Observational
Fatih Sultan Mehmet Training and Research Hospital
About 128 people
Starts Aug 16, 2026 (estimated)
In plain words An observational study of magnesium in people 18 and older, run by Fatih Sultan Mehmet Training and Research Hospital. It plans to enroll about 128 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Lipedema; Magnesium.
Serum magnesium levels must have been measured within the past 6 month
Be at least 18 years of age
Have a diagnosis of lipedema based on the Wold criteria
Have no cognitive or mental health issues
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Magnesium
Registered summary
Female patients diagnosed with lipedema will be divided into two groups based on their Pittsburgh Sleep Quality Index (PSQI) scores: PSQI ≤ 5 and PSQI \> 5. Age, body mass index (BMI), education level, menopausal status (reproductive period, perimenopausal period, postmenopausal period), number of births, duration of illness, occupation, marital status, disease stage, lipedema type, lower extremity functional scale, and the World Health Organization Quality of Life Scale - Short Form (Physical Health, Psychological Health, Social Relationships...)
Where, as registered
No sites listed yet.
Not yet recruitingNCT07147972
Comparative Study of Nutraceuticals vs. Conventional Prophylactic Therapy in the Management of Migraine
Phase 3
Fayoum University
About 100 people
Starts Aug 20, 2025 (estimated)
In plain words A Phase 3 study of magnesium in people 18 and older, run by Fayoum University. It plans to enroll about 100 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Migraine; Nutraceuticals.
Adults aged 18-60 years
- Diagnosed with episodic migraine (ICHD-3 criteria)
- ≥4 migraine attacks/month for the past 3 months
- Willing to provide informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Propranolol 80 mg; Magnesium 400Mg
Registered summary
Migraine is a common disabling neurological condition that significantly affects quality of life. While traditional prophylactic treatments (e.g., beta-blockers, antiepileptics) are effective, they may be associated with side effects leading to poor adherence. Recent evidence suggests that nutraceuticals like magnesium, riboflavin, and coenzyme Q10 may provide a safer alternative. This study aims to compare the efficacy and tolerability of these two approaches.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07427914
Effectiveness and Safety of Benemix® in Constipation
No phase
Universidad de Antioquia
About 80 people
Starts Jul 2026 (estimated)
In plain words A study of magnesium in people 18 and older, run by Universidad de Antioquia. It plans to enroll about 80 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Constipation - Functional.
Adults (≥18 years old) who use Benemix® for the management of constipation.
Participants who are using the product for the first time.
The exclusion criteria are on the listing.
What it tests, as registered
Benemix®, a functional food composed of turmeric, onion, magnesium, and lactose-free, skimmed milk powder
Registered summary
The goal of this clinical trial is to find out whether the functional food Benemix® helps treat constipation in adults and whether it is safe to use. The main questions this study aims to answer are: Does Benemix® help improve bowel movement frequency and consistency in adults with constipation? What medical problems, if any, do participants experience while taking Benemix®? Adults with constipation will take Benemix® every day for 15 days. During the second week, participants will have either an in-person clinic visit or a telemedicine appointment for checkups and tests. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07346469
Exploring the Effects of Magnesium Ions on Peripheral Neuropathy, Serum Magnesium Ion Concentration,Sleep Quality, and Quality of Life in Patients With Colorectal Cancer Receiving Chemotherapy.
No phase
Kaohsiung Medical University Chung-Ho Memorial Hospital
About 75 people
Starts Jan 1, 2026 (estimated)
In plain words A study of magnesium in people 20 and older, run by Kaohsiung Medical University Chung-Ho Memorial Hospital. It plans to enroll about 75 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: Colorectal Cancer (CRC); Chemotherapy Induced Peripheral Neuropathy (CIPN); Sleep Quality; Quality of Life (QOL).
a. Patients diagnosed with colorectal cancer by pathology.
b. Age ≥ 20 years.
c. Conscious.
d. Able to communicate fluently in Mandarin and Taiwanese.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
oral magnesium ions; oral magnesium ions and warm water with Gu Bao Sapindus mukorossi magnesium ion solution
Registered summary
Chemotherapy for colorectal cancer (CRC) is frequently complicated by chemotherapy-induced peripheral neuropathy (CIPN) and impaired sleep quality, significantly impacting patient quality of life. Low magnesium levels have been implicated in peripheral nerve dysfunction. This interventional study aims to investigate the effects of magnesium supplementation on serum magnesium concentration, CIPN severity, and sleep quality in CRC patients undergoing chemotherapy. Study Design and Methods This is a prospective, parallel-group, randomized controlled trial (RCT) utilizing a longitudinal design. The full summary is on the listing.
In plain words A study of magnesium in female participants 40 to 60, run by Guangdong Provincial People's Hospital. It plans to enroll about 50 people at 1 site, none in the US.
Postmenopausal status or in the late menopausal transition stage. 3. Postmenopausal status is defined as: natural menopause with no menstruation in the past 12 months.
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium-L-Threonate; Placebo
Registered summary
This trial has a randomized, single-blind, single-center, parallel-controlled design, with participant screening and trial implementation conducted at Guangdong Provincial People's Hospital. The study evaluate the efficacy of oral magnesium L-threonate supplementation on improving menopausal symptoms and quality of life among peri/post-menopausal women. This trial aims to explore whether oral magnesium L-threonate supplementation could alleviate menopausal syndromes. Participants will randomly assigned to conduct oral magnesium L-threonate supplementation or placebo for 8 weeks. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07322120
Light Fasting Diet and Magnesium in Polycystic Ovary Syndrome (PCOS)
No phase
Behnood Abbasi
About 46 people
Starts Feb 20, 2026 (estimated)
In plain words A study of magnesium in female participants 19 to 65, run by Behnood Abbasi. It plans to enroll about 46 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 19 to 65. Conditions: Polycystic Ovary Syndrome.
People between the ages of 19 and 65
People with a body mass index (BMI) ≤ 25
Diagnosis of polycystic ovary syndrome by a specialist based on the Rotterdam criteria
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, which is associated with hormonal imbalances, dyslipidemia, chronic inflammation, and increased oxidative stress, and can increase the risk of cardiovascular and metabolic diseases. Evidence suggests that nutritional interventions play an important role in improving metabolic outcomes in these patients. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07865351
Whole-Food Magnesium for Mental and Cardiometabolic Health
No phase
George Mason University
About 45 people
Starts Nov 2026 (estimated)
In plain words A study of magnesium in people 40 to 70, run by George Mason University. It plans to enroll about 45 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 70. Conditions: Elevated Blood Glucose.
Age 40-70 years
BMI 18.5-29.9 kg/m²
HbA1c 5.7%-6.4%
Stable medication regimen for at least 3 months
1 more inclusion criterion and the exclusion criteria are on the listing.
This randomized, double-blind, placebo-controlled clinical trial will evaluate the effects of daily supplementation with E-Z Mg™, a commercially available whole-food-based magnesium supplement, on sleep, mood, fatigue, and cardiometabolic health in adults with elevated blood glucose. The study will enroll 45 adults aged 40-70 years with HbA1c 5.7%-6.4% and BMI 18.5-29.9 kg/m². The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07756164
The Effects of a Multicomponent Sleep & Recovery Supplement on Muscle Fatigue and Sleep
No phase
University of Exeter
About 25 people
Starts Aug 2026 (estimated)
In plain words A study of magnesium in people 18 to 40, run by University of Exeter. It plans to enroll about 25 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40; healthy volunteers accepted. Conditions: Athletes; Healthy.
Aged between 18-40, healthy and non smokers
Recreationally active, exercise at least 2 times a week
The goal of this clinical trial (randomised crossover study) is to learn if a multi-component sleep and exercise recovery supplement can improve sleep quality and enhance recovery following exercise in healthy, recreationally active adults aged 18-40. The main questions it aims to answer are: 1. Does the supplement reduce delayed onset muscle soreness (DOMS) following an intense exercise protocol? 2. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07475299
Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome
No phase
Iuliu Hatieganu University of Medicine and Pharmacy
About 8 people
Starts Apr 2026 (estimated)
In plain words A study of magnesium in people 18 to 70, run by Iuliu Hatieganu University of Medicine and Pharmacy. It plans to enroll about 8 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Irritable Bowel Syndrome (IBS).
Adults aged ≥18 years
Clinically confirmed diagnosis of Irritable Bowel Syndrome documented in the medical record
Presence of recurrent gastrointestinal symptoms such as bloating, abdominal discomfort, gas, or bowel habit disturbances (constipation, diarrhea, or mixed pattern) considered clinically relevant by the participant
Ability to understand the study procedures and provide written informed consent
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Synbiotic supplement containing probiotic strains, botanical extracts, magnesium, vitamin B1, and L-theanine designed to support gut microbiota balance.
Registered summary
The goal of this clinical trial is to evaluate whether a synbiotic dietary supplement containing botanical extracts and multiple probiotic strains can improve gastrointestinal symptoms and modulate gut microbiota composition in adults diagnosed with Irritable Bowel Syndrome (IBS). The full summary is on the listing.